Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Milestone Pharmaceuticals Inc (MIST)

Milestone Pharmaceuticals Inc (MIST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 96,524
  • Shares Outstanding, K 53,328
  • Annual Sales, $ 1,000 K
  • Annual Income, $ -59,690 K
  • EBIT $ -49 M
  • EBITDA $ -49 M
  • 60-Month Beta 1.72
  • Price/Sales 98.12
  • Price/Cash Flow N/A
  • Price/Book 4.08

Options Overview Details

View History
  • Implied Volatility 200.91% ( +63.19%)
  • Historical Volatility 55.64%
  • IV Percentile 63%
  • IV Rank 28.04%
  • IV High 695.03% on 04/05/24
  • IV Low 8.39% on 12/15/23
  • Put/Call Vol Ratio 0.05
  • Today's Volume 20
  • Volume Avg (30-Day) 81
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,873
  • Open Int (30-Day) 1,176

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.16
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.17
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4000 +21.43%
on 11/01/24
2.1000 -19.05%
on 11/07/24
+0.2100 (+14.09%)
since 10/15/24
3-Month
1.2900 +31.78%
on 08/16/24
2.1000 -19.05%
on 11/07/24
+0.3500 (+25.93%)
since 08/15/24
52-Week
1.1200 +51.79%
on 07/02/24
3.5200 -51.70%
on 12/05/23
-0.5700 (-25.11%)
since 11/15/23

Most Recent Stories

More News
Milestone Pharmaceuticals: Q3 Earnings Snapshot

Milestone Pharmaceuticals: Q3 Earnings Snapshot

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals: Q2 Earnings Snapshot

Milestone Pharmaceuticals: Q2 Earnings Snapshot

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals: Q1 Earnings Snapshot

Milestone Pharmaceuticals: Q1 Earnings Snapshot

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a fireside chat at the Piper...

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals: Q3 Earnings Snapshot

Milestone Pharmaceuticals: Q3 Earnings Snapshot

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYSTâ„¢, the conditionally approved brand name for etripamil nasal spray, for...

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation...

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the Company will host a virtual investor and analyst webcast on Monday, November...

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil

Submission seeks approval for treatment of an abnormal heart rhythm, Paroxysmal Supraventricular Tachycardia or PSVT Comprehensive data package includes...

MIST : 1.7000 (-6.08%)

Business Summary

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 1.9100
2nd Resistance Point 1.8600
1st Resistance Point 1.7800
Last Price 1.7000
1st Support Level 1.6500
2nd Support Level 1.6000
3rd Support Level 1.5200

See More

52-Week High 3.5200
Fibonacci 61.8% 2.6032
Fibonacci 50% 2.3200
Fibonacci 38.2% 2.0368
Last Price 1.7000
52-Week Low 1.1200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar